Collectively, our identification of ZBTB20 as a critical regulator of ChREBP provides novel insight into the hierarchy of transcriptional regulatory network of hepatic lipogenesis, which will help to unravel the biochemical basis of NAFLD and develop a therapeutic approach to this disease. This evidence concerns the gene MLXIPL and metabolic dysfunction-associated steatotic liver disease.